Corbus announces Phase 1 data for CRB-701: 43% ORR at therapeutic doses, no peripheral neuropathy or skin rash

Corbus Pharmaceuticals Holdings, Inc.

Phase 1 dose-escalation data for CRB-701 (SYS6002) in nectin-4 positive tumors presented at ASCO GU 2024.
At doses ≥2.7 mg/kg (n=7), ORR 43% (3 partial responses) and disease control rate 71%; no grade 3+ adverse events.
No dose-limiting toxicities, peripheral neuropathy, or skin rash observed; dose escalation ongoing at 4.5 mg/kg.
CRB-701 showed lower free MMAE exposure vs enfortumab vedotin; longest ongoing response ~10 months.
U.S. clinical study expected to start in Q1 2024 under already-open IND.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.